SEMA3A and amyotrophic lateral sclerosis: Moreover, ALS mice with specific knockout of the Semaphorin3A receptor, NRP1, or treated with a monoclonal antibody interfering with SEMA3A-NRP1 signaling, exhibited improved function and prolonged survival [129,130].